Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680692 | 0.83 | MEN1 (0.47) | CYP19A1ALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL29770616 | 0.83 | MEN1 (0.47) | CYP19A1ALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL17423720 | 0.82 | CYP19A1 (0.68) | CYP19A1LMNATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23067813 | 0.81 | TGFBR1 (0.48) | CYP19A1GRM5TGFBR1 | |
| SCHEMBL29921036 | 0.81 | TGFBR1 (0.48) | CYP19A1GRM5TGFBR1 | |
| SCHEMBL12562322 | 0.81 | CYP19A1 (0.71) | CYP19A1LMNATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL522790 | 0.79 | CYP19A1 (1.00) | CYP19A1LMNATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3539048 | 0.78 | CYP19A1 (0.40) | CYP19A1LMNATDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5318849 | 0.78 | MAOB (0.51) | CYP19A1ALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL23900708 | 0.78 | ALOX5AP (0.47) | CYP19A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477629-B1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | UNIV VANDERBILT (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172248-A1 | SUBSTITUTED HETEROARYLAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | CYP19A1 4208/4885LMNA 4679/4885TDP1 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.